OBJECTIVES: To investigate the effect of different iodine concentrations at either constant injection or iodine administration rates but constant total iodine load on contrast enhancement of liver, pancreas and spleen by multidetector row CT. MATERIALS AND METHODS: One hundred and twenty consecutive patients (70+/-6 years) underwent triphasic liver CT at a four-channel multidetector-row CT using the non-ionic contrast medium iopromide. Patients were divided into six equal groups-I: 150 ml, 240 mg/ml at 4 ml/s; II: 120 ml, 300 mg/ml at 4 ml/s; III: 97.3 ml, 370 mg/ml at 4 ml/s; IV: 150 ml, 240 mg/ml at 5 ml/s; V: 120 ml, 300 mg/ml, 60 ml at 6 ml/s, 60 ml at 3 ml/s; VI: 97.3 ml, 370 mg/ml at 3.3 ml/s. ROIs were measured in the liver, the pancreas, and the spleen in unenhanced, arterial, portal venous, and equilibrium phase. RESULTS: At a constant injection rate of 4 ml/s, pancreatic enhancement over baseline only in the arterial phase was significantly higher at 370 mg/ml (58+/-15 HU versus 59+/-18 HU versus 74+/-20 HU for groups I-III, respectively (p<0.02)). Comparison of different iodine concentrations at constant iodine administration rate (groups II, IV and VI) and of all six protocols revealed no significant differences at either phase. CONCLUSIONS: At a constant iodine load and constant injection rates, the high-iodinated contrast agent iopromide at 370 mg/ml improves pancreatic enhancement in the arterial phase. At constant iodine load and constant iodine administration rates, there is no significant effect of different iodine concentrations.
OBJECTIVES: To investigate the effect of different iodine concentrations at either constant injection or iodine administration rates but constant total iodine load on contrast enhancement of liver, pancreas and spleen by multidetector row CT. MATERIALS AND METHODS: One hundred and twenty consecutive patients (70+/-6 years) underwent triphasic liver CT at a four-channel multidetector-row CT using the non-ionic contrast medium iopromide. Patients were divided into six equal groups-I: 150 ml, 240 mg/ml at 4 ml/s; II: 120 ml, 300 mg/ml at 4 ml/s; III: 97.3 ml, 370 mg/ml at 4 ml/s; IV: 150 ml, 240 mg/ml at 5 ml/s; V: 120 ml, 300 mg/ml, 60 ml at 6 ml/s, 60 ml at 3 ml/s; VI: 97.3 ml, 370 mg/ml at 3.3 ml/s. ROIs were measured in the liver, the pancreas, and the spleen in unenhanced, arterial, portal venous, and equilibrium phase. RESULTS: At a constant injection rate of 4 ml/s, pancreatic enhancement over baseline only in the arterial phase was significantly higher at 370 mg/ml (58+/-15 HU versus 59+/-18 HU versus 74+/-20 HU for groups I-III, respectively (p<0.02)). Comparison of different iodine concentrations at constant iodine administration rate (groups II, IV and VI) and of all six protocols revealed no significant differences at either phase. CONCLUSIONS: At a constant iodine load and constant injection rates, the high-iodinated contrast agent iopromide at 370 mg/ml improves pancreatic enhancement in the arterial phase. At constant iodine load and constant iodine administration rates, there is no significant effect of different iodine concentrations.
Authors: F F Behrendt; A H Mahnken; S Keil; M Das; C Hohl; D Bauer; P Seidensticker; E Jost; J E Wildberger; R W Günther; G Mühlenbruch Journal: Eur Radiol Date: 2008-01-29 Impact factor: 5.315
Authors: S Keil; C Plumhans; F F Behrendt; M Das; S Stanzel; G Mühlenbruch; P Seidensticker; C Knackstedt; A H Mahnken; R W Günther; J E Wildberger Journal: Eur Radiol Date: 2008-04-08 Impact factor: 5.315
Authors: Georg Mühlenbruch; Florian F Behrendt; Mohammed A Eddahabi; Christian Knackstedt; Sven Stanzel; Marco Das; Peter Seidensticker; Rolf W Günther; Joachim E Wildberger; Andreas H Mahnken Journal: Eur Radiol Date: 2008-07-24 Impact factor: 5.315